ProPhase Labs Inc  

(Public, NASDAQ:PRPH)   Watch this stock  
Find more results for PRPH
1.34
-0.01 (-0.74%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.30 - 1.35
52 week 1.21 - 2.23
Open 1.30
Vol / Avg. 9,350.00/21,209.00
Mkt cap 21.30M
P/E     -
Div/yield     -
EPS -0.45
Shares 15.89M
Beta 1.20
Inst. own 26%
Mar 25, 2015
Q4 2014 ProPhase Labs Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -7.53% -35.50%
Operating margin -7.51% -35.47%
EBITD margin - -18.01%
Return on average assets -15.96% -46.80%
Return on average equity -25.51% -67.21%
Employees 54 -
CDP Score - -

Address

621 N Shady Retreat Rd
DOYLESTOWN, PA 18901-2514
United States - Map
+1-215-3450919 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a ranges of homeopathic and health products. The Company is also engaged in the research and development of potential over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. The Company's primary business is manufacturing, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. The Company's flagship brand is Cold-EEZE Cold Remedy and the Company's principal product is Cold-EEZE zinc gluconate lozenges, are used to reduce the duration and severity of symptoms of the common cold. During the fiscal year ended December 31, 2013, the Company expanded its Cold-EEZE Cold Remedy QuickMelts product line with two new products, Cold-EEZE Plus Immune Support QuickMelts and Cold-EEZE Plus Immune Support plus Energy QuickMelts.

Officers and directors

Ted William Karkus Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Robert V. Cuddihy Jr. Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Mark A. Burnett Independent Director
Age: 54
Bio & Compensation  - Reuters
Mark Shawn Frank Independent Director
Age: 52
Bio & Compensation  - Reuters
Louis Gleckel M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Mark Leventhal Independent Director
Age: 65
Bio & Compensation  - Reuters
James T. McCubbin Independent Director
Age: 50
Bio & Compensation  - Reuters